• Home>
  • La Roche-Posay clinical studies: at the heart of our design process

Proven efficacy. Clinically demonstrated tolerance

La Roche-Posay clinical studies:
at the heart of our design process

Every day, our teams devote all their energy to creating expert skincare designed to offer a better life to people with sensitive skin - skincare that boasts an optimal safety level with each application. To keep this promise, we have chosen to put a particularly demanding design method at the heart of our process. It was following a first series of studies carried out on healthy skin that La Roche-Posay Dermatological Laboratory was able to perform trials specially designed to observe our skincare's effectiveness and tolerance on the product's specific targets (atopy-prone skin, acne-prone skin and very dry skin). These complex and ambitious studies are the keystone to the development of our products and the sensitive skin expertise in which we specialise.

In total, 520 clinical studies involving 45,000 patients from all over the world will have been carried out in close collaboration with dermatologists since the creation of the La Roche-Posay Dermatological Laboratory. These highly regulated trials follow protocols similar to those of the pharmaceutical industry and have given rise to numerous scientific publications in renowned dermatology journals, representing real recognition of our commitment and the quality of our scientific approach.

Better understanding a clinical trial video

In this video, discover how La Roche-Posay Dermatological Laboratory has been able to observe and analyse  Effaclar Duo (+)
 's results during a clinical trial carried out in China. Performed on the half-face, this study made it possible to compare the performance of this exclusive skincare with that of a formula without an active ingredient, while avoiding variability between individuals. It clinically demonstrated the anti-blemish and anti-mark effectiveness1 of a product that changes the everyday life of acne-prone skin day after day:

1Dermatological scoring of inflammatory lesions (4 weeks, 51 women, phototypes I and II).